SURVYR

PRAX

Praxis Precision Medicines, Inc.
$267.59
+$0.20 (0.07%)Oct 27 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-17%+15%+47%+79%+111%Oct 2025Oct 2026Apr 202652w high $392.7052w low $154.45
PRAXSPY
Wall St. Highest PT $1,201.00 (+348.8%) Wall St. Avg PT $650.00 (+142.9%)
$164$482$800$1,118$1,436POC $315Hi $1,201Avg $650
Underwater Drawdown %Max DD -38.1%Current -30.7%
0.0%-38.1%
Relative Strength vs SPY+30.4% vs SPYOutperforming
+109%0%-109%
1W
+$3.10 (1.17%)
1M
−$13.19 (4.70%)
3M
−$28.22 (9.54%)
6M
−$54.33 (16.88%)
YTD
−$27.15 (9.21%)
1Y
+$81.65 (43.91%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
21 analysts · mean score 1.48
1 = Strong Buy · 5 = Sell
Strong Buy1571%
Buy419%
Hold15%
Underperform00%
Sell15%
Wall Street consensus · as of Oct 21, 2026
Analyst price targets
Current price$267.59
Average target$650.00
+$382.41 (+142.9%) upsideaverage target vs current price
CurrentAverageMedian
Low$188.00
Median$582.00
High$1,201.00
12-month Wall Street target range · as of Oct 21, 2026

Third-party ratings, not SURVYR.'s views.

Health check

Financial health
DistressGrey zoneSafe
Safe zone
Altman Z-score 87.7
Above 2.99 is the safe zone, below 1.81 the distress zone.
Quality
WeakAverageStrong
Weak
Piotroski F-score 3 of 9
See the tests
  • ✗Positive net income
  • ✗Positive operating cash flow
  • ✓Return on assets improved
  • ✓Cash flow above net income
  • ✓Long-term debt / assets fell
  • ✗Current ratio improved
  • ✗No share dilution
  • ✗Gross margin improved
  • ✗Asset turnover improved

Computed by SURVYR. from the company's SEC filings (latest balance sheet Jun 30, 2026). Descriptive, not a forecast.

Key stats & company

Market value$7.3B
P/E (next 12 months, estimated)-27.5
52-week range$154.45 – $392.70
Dividend yieldNo dividend
Analyst consensusStrong Buy (21)
Average analyst price target$650.00 (+143%)

What they do

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Bottom line
No cash-flow valuation
Model read-out from the numbers below, not advice. Score +0 (DCF counts double).
▼Piotroski F-score3/9
▲Altman Z87.7 (safe)
▲Analyst target+143% (21 analysts)

Discounted cash flow

Trailing free cash flow is negative or missing, so a cash-flow DCF isn't meaningful by default. You can enter your own assumptions below.
Reverse DCFfor context, not a signal
Trailing free cash flow is zero or negative, so there's no growth rate to solve for. The price is betting on a turnaround to positive cash flow.
Edit assumptions · recalculates instantly
Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (FY to 2025-12-31). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 2.81 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs sector

Forward EPS $-9.50 vs trailing $-12.95. Forward P/E uses analysts' next-12-month estimate.

Quality & financial health

Gross margin
–
Operating margin
–
FCF margin
–
Net margin
–
Return on equity
-25.3%
Return on invested capital
-51.3%
Net debt / EBITDA
–
Current ratio
15.7×
Interest cover
–
Cash conversion (OCF/NI)
–
Piotroski F-score 3/9 · last two fiscal years
✗ Positive net income✗ Positive operating cash flow✓ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✗ Current ratio improved✗ No share dilution✗ Gross margin improved✗ Asset turnover improved

Altman Z-score 87.7 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target
$650
+143%
Analysts
21
Strong Buy
Range
$188–$1,201
low – high
● price · ◆ mean target

Annual history

FYRevenueNet incomeFree cash flow
2025$0$-303.3M$-249.1M
2024$8.6M$-182.8M$-131.8M
2023$2.4M$-123.3M$-111.2M
2022$0$-214.0M$-185.5M

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR –.

For information only · Important disclosures

Grades vs sector

No sector grades for PRAX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Held by 1 of 7 live models: New Highs Growth.

New Highs Growth
4.0% of the book
 HeldQuality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book
Why it's in the New Highs Growth

Qualified on Biotech, -25% from 52-week high, biotech, price-only entry, 12-1 momentum +569%.

What would knock it out: Drops out if it falls outside the top 25 at the next rebalance (Oct 30). In the latest preview (2026-10-27) it is outside the top 25.

Earnings & events

PRAX earningsNext report in 13 days
Next report
Mon Nov 9, 2026Before the open
EPS consensus-$3.63
Revenue consensus–
Last 4 quarters · EPS vs estimate
Aug 6, 2026-$2.87est -$3.69+22.2%Above estimates
May 7, 2026-$3.20est -$3.68+13.0%Above estimates
Feb 19, 2026-$3.50est -$3.13−12.0%Below estimates
Nov 5, 2025-$3.36est -$3.49+3.7%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-21 18:16:06 ET
24-1125-0225-0525-0825-1126-0226-0526-08-3.690.00
EstimateActual (beat)Actual (miss)

News & catalysts

More news
No recent headlines.

Research

New Highs Growth: rebalance of Sep 30, 2026Oct 22, 2026

Stats refreshed 2026-10-21 18:16:06 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026